Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006237 · ClinicalTrials.gov registry record · Phase 3
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT00006237 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 432 participants.
The verdict
NCT00006237, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa is more effective with or without combination chemotherapy and interleukin-2 for melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy consisting of cisplatin, vinblastine, and dacarbazine, plus interleukin-2, in treating patients who have melanoma.
Interventions
- DRUG cisplatin
- DRUG dacarbazine
- BIOLOGICAL filgrastim
- BIOLOGICAL interleukin-2
- BIOLOGICAL interferon alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2000-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006237
The ClinicalTrials.gov registry entry for NCT00006237 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00006237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006237 about?
NCT00006237 is a clinical study titled "S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interfer...
What is the current status of trial NCT00006237?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2000-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00006237?
The interventions under investigation include: cisplatin (DRUG), dacarbazine (DRUG), filgrastim (BIOLOGICAL), interleukin-2 (BIOLOGICAL), interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006237?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.